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Capsule summary  55 
• SERPINB7 mutations in NPPK are not confined to Asian populations.  56 
• The presence of SERPINB7 mutations should be tested in patients with NPPK in non-Asian 57 





To the editor: Nagashima-type palmoplantar keratosis (NPPK) is an autosomal recessive PPK caused by 59 
mutations in the serpin family B member 7 (SERPINB7) gene.
1
 It has been reported only in Japanese, 60 
Chinese and Korean populations, with a common founder mutation c.796C>T p.(Arg266*).
1,2,3
 NPPK is 61 
characterized by well-demarcated, mild, nonprogressive diffuse hyperkeratosis with transgredient 62 
erythema expanding onto the dorsal aspect of the hands, wrists and Achilles tendon area.  Palmoplantar 63 
hyperhidrosis, aquagenic whitening and fungal infections are frequent.
1,4
 Loss of functional SERPINB7 in 64 
skin probably leads to overactivation of intracorneocyte proteases causing skin barrier defects with 65 
hyperkeratosis, mild inflammation, and increased water permeability.
1
  66 
We report three non-Asian NPPK patients, with a typical NPPK phenotype and homozygous SERPINB7 67 
mutation. Since the age of two months, the 27-year-old Finnish male proband (P1) had a mild diffuse PPK 68 
with a well demarcated erythema extending to the wrist and Achilles tendon area (Fig 1, Table I). His whole 69 
exome sequencing (WES) (SuppText1) revealed a homozygous SERPINB7 c.1136G>A p.(Cys379Tyr) 70 
(NM_003784.3) variant (rs201208667) in exon 8 encoding the second-last amino acid of SERPINB7. His 71 
unaffected mother and sister were heterozygous carriers of the variant. Sanger sequencing among 44 72 
unrelated Finnish PPK patients revealed two other homozygous patients and four heterozygous carriers 73 
(Table I). WES of three heterozygous patients (P4-P6) revealed no other likely pathogenic variants or copy-74 
number variations (CNVs) in SERPINB7 or other genes.  WES was unfeasible for P7 but a SNP array for 75 
haplotype analysis revealed no other SERPINB7 variants or CNVs. The cause of their PPK thus remains 76 
unknown. Other plausible SERPINB7 variants were not analyzed in the other patients. 77 
SERPINB7 c.1136G>A p.(Cys379Tyr) has not been reported in NPPK (SuppTable1). It was predicted 78 
damaging by SIFT, Polyphen, MutationTaster, LRT and CADD (score 19).  Only heterozygous carriers were 79 
found in population allele frequency databases (ExAC, GnomAD and SISu). According to GnomAD, the 80 
heterozyogous carrier frequency was significantly higher for the Finnish population (0.006397) than for 81 
non-Finns (0.00032-0.0014), indicating a 5 to 20-fold enrichment in Finns. A common haplotype spanning 82 





genome wide SNP array data (SuppTable2). The variant thus constitutes a plausible Finnish NPPK founder 84 
mutation.  85 
P1’s skin histology showed non-epidermolytic hyperkeratosis compatible with NPPK.  SERPINB7 86 
immunostaining was strong throughout the stratum spinosum (SS) with most intense staining in stratum 87 
granulosum. Heterozygous carriers and healthy controls showed less intense staining throughout the SS 88 
and the lower SS was negative (SuppFigure 1). Thus, the c.1136G>A p.(Cys379Tyr) mutation apparently 89 
leads to aberrant SERPINB7 distribution within the SS.  90 
 91 
The c.1136G>A p.(Cys379Tyr) SERPINB7 variant changes the second-last amino acid cysteine, which is 92 
conserved among different species (SuppFigure2). Tertiary structure prediction suggested that the 93 
substitution is in the vicinity of the reactive site loop (RSL) where most SERPINB7 mutations in NPPK are 94 
located. The substitution possibly affects the conformational mobility of RSL during the inhibition process.
 5
  95 
Previously NPPK has been reported exclusively in Asian patients. Our findings encourage assessment for 96 
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NPPK: Nagashima type palmoplantar keratoderma 103 
PPK: palmoplantar keratoderma 104 
SERPINB7: serpin family B member 7 105 
WES: Whole exome sequencing  106 
CNV: copy-number variation 107 
RSL: reactive site loop  108 
SiSU: Sequencing Initiative Suomi project  109 
SS: stratum spinosum 110 
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Figure legends 126 
Figure 1. NPPK clinical characteristics.  Mild palmoplantar hyperkeratosis with transgredient erythema 127 
extending to the wrist and Achilles tendon area in P1 homozygous for SERPINB7 c.1136G>A.  128 
 129 
Table legends 130 
Table I. Clinical characteristics of the patients.  131 
 132 
Supplemental material on Mendeley platform 133 
SuppTable1. SERPINB7 mutations in NPPK. Founder mutations are highlighted in bold.  134 
SuppTable2. Shared haplotype around SERPINB7 c.1136G>A p.(Cys379Tyr) variant (rs201208667). Two 135 
homozygous patients and six heterozygous carriers show the common shared 272 kb haplotype delineated 136 
by the black lines. Shared haplotype regions are shaded light grey and the c.1136G>A p.(Cys379Tyr) variant 137 
is bolded and shaded dark grey. The haplotypes of P1, P1’s mother and sister and P2 extend beyond the 138 
region shown. 139 
SuppText1. Materials and methods. 140 
SuppFigure1. NPPK clinical characteristics and SERPINB7 immunohistochemistry.  141 






Table I. Clinical characteristics of the patients. 144 
*WES, whole exome sequencing done +/ not done 145 







A/A A/A A/A G/A G/A G/A G/A G/A G/A - 
WES* + - - + +  + - - -  
Age years 27  18  11  60  21 12 16 66 32  
Gender male male male male female female male female female  




birth 9 years  - - birth to 9-
10 years 
Diffuse mild PPK  + + + + + + + - - + 
Transgredient + + + + + + + - - + 
Achilles tendon 
affected 
+ + + - + + - - - + 
Wrists affected + + + - + + - - - + 
Progrediens - - - - - - - - - - 
Hyperhidrosis + + + + + + + - - + /- 
Aquagenic whitening + + + N/A + + - - - + 
Fungal infections + - - - + + + - - + 
Knee/elbow 
hyperkeratosis 
- - - - - - - - - + /- 
11 
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